Maximum acceptable risk of serious infections, blood clots and negative sperm effects
| Attribute | Attribute change | MAR of blood clots (95% CI) | MAR of serious infections (95% CI) | MAR of negative effects on sperm (95% CI) | |||||
| From | To | Overall | Male | Female | Overall | Male | Female | Male | |
| How and how often the DMARD is taken | Injection weekly | Oral daily | 1.1% | 1.8% | 0.8% | 1.5% | 2.5% | 1.0% | 7.4% |
| (0.7%; 1.6%) | (0.9%; 2.8%) | (0.4%; 1.2%) | (0.9%; 2.1%) | (1.0%; 4.0%) | (0.5%; 1.6%) | (4.2%; 10.7%) | |||
| Injection biweekly | Oral pill daily | 0.8% | 0.9% | 0.7% | 1.0% | 1.3% | 0.9% | 5.1% | |
| (0.3%; 1.2%) | (<0.1%; 1.8%) | (0.3%; 1.1%) | (0.4%; 1.6%) | (<−0.1%; 2.6%) | (0.4%; 1.4%) | (2.0%; 8.2%) | |||
| Difficulty with daily activities | Moderate | Mild | 1.5% | 1.5% | 1.4% | 1.9% | 2.1% | 1.9% | 21.8% |
| (1.0%; 1.9%) | (0.6%; 2.4%) | (1.0%; 1.8%) | (1.3%; 2.5%) | (0.8%; 3.3%) | (1.3%; 2.4%) | (15.7%; 27.8%) | |||
| Severe | Mild | 3.2% | 3.2% | 3.3% | 4.3% | 4.3% | 4.3% | 12.0% | |
| (2.6%; 3.9%) | (1.9%; 4.4%) | (2.7%; 3.9%) | (3.4%; 5.2%) | (2.5%; 6.2%) | (3.5%; 5.1%) | (8.4%; 15.6%) | |||
| Severe | Moderate | 1.8% | 1.6% | 1.9% | 2.4% | 2.3% | 2.4% | 9.7% | |
| (1.4%; 2.2%) | (0.8%; 2.5%) | (1.5%; 2.2%) | (1.8%; 2.9%) | (1.1%; 3.5%) | (1.9%; 3.0%) | (6.2%; 13.2%) | |||
| Risk of serious infections | 2% | 0% | 1.5% | 1.5% | 1.5% | – | – | – | 10.2% |
| (1.3%; 1.7%) | (1.1%; 1.9%) | (1.3%; 1.7%) | – | – | – | (7.9%; 12.5%) | |||
| 3% | 0% | 2.3% | 2.2% | 2.3% | – | – | – | 15.3% | |
| (2.0%; 2.6%) | (1.6%; 2.9%) | (2.0%; 2.6%) | – | – | – | (11.8%; 18.8%) | |||
| 6% | 0% | 4.6% | 4.5% | 4.6% | – | – | – | 30.6% | |
| (4.0%; 5.1%) | (3.2%; 5.7%) | (4.0%; 5.2%) | – | – | – | (23.6%; 37.6%) | |||
| Amount of pain | 30 | 10 | 1.6% | 2.3% | 1.2% | 2.0% | 3.2% | 1.6% | 10.4% |
| (1.3%; 1.8%) | (1.7%; 3.0%) | (1.0%; 1.5%) | (1.7%; 2.4%) | (2.1%; 4.2%) | (1.23%; 2.0%) | (8.0%; 13.0%) | |||
| 60 | 10 | 3.9% | 5.8% | 3.06% | 5.1% | 7.9% | 4.0% | 26.1% | |
| (3.2%; 4.5%) | (4.2%; 7.4%) | (2.4%; 3.7%) | (4.2%; 6.1%) | (5.3%; 10.5%) | (3.1%; 4.9%) | (19.7%; 32.4%) | |||
| 60 | 30 | 2.3% | 3.5% | 1.8% | 3.1% | 4.8% | 2.4% | 15.6% | |
| (1.9%; 2.7%) | (2.5%; 4.5%) | (1.4%; 2.2%) | (2.5%; 3.6%) | (3.2%; 6.3%) | (1.8%; 3.0%) | (12.0%; 19.4%) | |||
| Risk of blood clots | 0.20% | 0% | – | – | – | 0.3% | 0.3% | 0.3% | 1.4% |
| – | – | – | (0.2%; 0.3%) | (0.2%; 0.4%) | (0.2%; 0.3%) | (1.1%; 1.6%) | |||
| 0.50% | 0% | – | – | – | 0.7% | 0.7% | 0.6% | 3.4% | |
| – | – | – | (0.6%; 0.7%) | (0.5%; 0.9%) | (0.6%; 0.7%) | (2.6%; 4.1%) | |||
| 1% | 0% | – | – | – | 1.3% | 1.4% | 1.3% | 6.7% | |
| – | – | – | (1.2%; 1.5%) | (1.0%; 1.8%) | (1.1%; 1.5%) | (5.3%; 8.2%) | |||
| Respondents | 2090 | ||||||||
| Observations | 18 810 | ||||||||
| Parameters | 55 | ||||||||
| Null log-likelihood | −13 038.1 | ||||||||
| Model log-likelihood | −5385.1 | ||||||||
DMARD, disease-modifying antirheumatic drug; MAR, maximum acceptable risk.